Yubin Miao

List of Publications by Year
in descending order

50	1,586	218677	289244
papers	citations	26	40
		h-index	g-index

51	51	51	1070
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Imaging of Melanoma Using64Cuâ˘ and86Yâ˘DOTAâ˘ReCCMSH(Arg11), a Cyclized Peptide Analogue of α-MSH. Journal of Medicinal Chemistry, 2005, 48, 2985-2992.	6.4	124
2	Melanoma Therapy via Peptide-Targeted α-Radiation. Clinical Cancer Research, 2005, 11, 5616-5621.	7.0	118
3	In vivo evaluation of188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. International Journal of Cancer, 2002, 101, 480-487.	5.1	88
4	99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. Journal of Nuclear Medicine, 2007, 48, 73-80.	5.0	74
5	Evaluation of the Human Melanoma Targeting Properties of Radiolabeled α-Melanocyte Stimulating Hormone Peptide Analogues. Bioconjugate Chemistry, 2003, 14, 1177-1184.	3.6	73
6	Peptide-targeted radionuclide therapy for melanoma. Critical Reviews in Oncology/Hematology, 2008, 67, 213-228.	4.4	66
7	Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. Journal of Nuclear Medicine, 2005, 46, 121-9.	5.0	65
8	^{111}In-Labeled Lactam Bridge-Cyclized α-Melanocyte Stimulating Hormone Peptide Analogues for Melanoma Imaging. Bioconjugate Chemistry, 2008, 19, 539-547.	3.6	57
9	Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. Journal of Nuclear Medicine, 2007, 48, 64-72.	5.0	57
10	[203]Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection. Journal of Nuclear Medicine, 2008, 49, 823-829.	5.0	53
11	Effects of the Amino Acid Linkers on the Melanoma-Targeting and Pharmacokinetic Properties of ^{111}In-Labeled Lactam Bridge–Cyclized α-MSH Peptides. Journal of Nuclear Medicine, 2011, 52, 608-616.	5.0	50
12	Reduction of the Ring Size of Radiolabeled Lactam Bridge–Cyclized α-MSH Peptide, Resulting in Enhanced Melanoma Uptake. Journal of Nuclear Medicine, 2010, 51, 418-426.	5.0	48
13	Tumor-targeting properties of 90Y- and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nuclear Medicine and Biology, 2005, 32, 485-493.	0.6	47
14	Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide. Nuclear Medicine and Biology, 2009, 36, 267-276.	0.6	41
15	Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nuclear Medicine and Biology, 2006, 33, 723-733.	0.6	38
16	Cu-64-Labeled Lactam Bridge-Cyclized α-MSH Peptides for PET Imaging of Melanoma. Molecular Pharmaceutics, 2012, 9, 2322-2330.	4.6	37
17	Gallium-67-Labeled Lactam Bridge-Cyclized Alpha-MSH Peptides with Enhanced Melanoma Uptake and Reduced Renal Uptake. Bioconjugate Chemistry, 2012, 23, 1341-1348.	3.6	36
18	Introduction of an 8-Aminooctanoic Acid Linker Enhances Uptake of ^{99m}Tc-Labeled Lactam Bridge–Cyclized α-MSH Peptide in Melanoma. Journal of Nuclear Medicine, 2014, 55, 2057-2063.	5.0	35

#	Article	IF	Citations
19	Therapeutic Efficacy of a ^{177}Lu-Labeled DOTA Conjugated α-Melanocyte-Stimulating Hormone Peptide in a Murine Melanoma-Bearing Mouse Model. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 333-341.	1.0	33
20	A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] $\alpha v \beta 3$/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nuclear Medicine and Biology, 2014, 41, 133-139.	0.6	33
21	Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Frontiers in Bioscience - Landmark, 2007, 12, 4514.	3.0	32
22	Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nuclear Medicine and Biology, 2010, 37, 873-883.	0.6	32
23	Design and Evaluation of New Tc-99m-Labeled Lactam Bridge-Cyclized Alpha-MSH Peptides for Melanoma Imaging. Molecular Pharmaceutics, 2013, 10, 1400-1408.	4.6	31
24	Gallium-67-Labeled Lactam Bridge-Cyclized α-Melanocyte Stimulating Hormone Peptide for Primary and Metastatic Melanoma Imaging. Bioconjugate Chemistry, 2009, 20, 2356-2363.	3.6	30
25	^{68}Ga-DOTA-GGNle-CycMSH$_{hex}$ targets the melanocortin-1 receptor for melanoma imaging. Science Translational Medicine, 2018, 10, .	12.4	30
26	Synthesis and Evaluation of Novel Gonadotropin-Releasing Hormone Receptor-Targeting Peptides. Bioconjugate Chemistry, 2011, 22, 1682-1689.	3.6	28
27	GABAA Receptor Availability Changes Underlie Symptoms in Isolated Cervical Dystonia. Frontiers in Neurology, 2018, 9, 188.	2.4	28
28	Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. Molecular Pharmaceutics, 2019, 16, 1694-1702.	4.6	26
29	Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2319-2323.	2.2	25
30	Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy. Nuclear Medicine and Biology, 2015, 42, 99-108.	0.6	25
31	Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer. Nuclear Medicine and Biology, 2018, 62-63, 71-77.	0.6	14
32	Novel [99mTc]-Tricarbonyl-NOTA-Conjugated Lactam-Cyclized Alpha-MSH Peptide with Enhanced Melanoma Uptake and Reduced Renal Uptake. Molecular Pharmaceutics, 2020, 17, 3581-3588.	4.6	14
33	Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy. Journal of Nuclear Medicine, 2021, 62, 313-318.	5.0	14
34	Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 597-603.	1.0	11
35	Dual receptor-targeting 99mTc-labeled Arg-Gly-Asp-conjugated Alpha-Melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nuclear Medicine and Biology, 2015, 42, 369-374.	0.6	10
36	Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5484-5487.	2.2	9

#	Article	IF	Citations
37	Imaging human melanoma using a novel Tc-99m-labeled lactam bridge-cyclized alpha-MSH peptide. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4724-4728.	2.2	9
38	Evaluation of novel 111 In-labeled gonadotropin-releasing hormone peptides for human prostate cancer imaging. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4647-4651.	2.2	8
39	Probing the Hydrogen Bonding of the Ferrous–NO Heme Center of nNOS by Pulsed Electron Paramagnetic Resonance. Journal of Physical Chemistry A, 2015, 119, 6641-6649.	2.5	6
40	Novel ^{64}Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios. Molecular Pharmaceutics, 2022, 19, 2535-2541.	4.6	6
41	Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4952-4955.	2.2	5
42	A docked state conformational dynamics model to explain the ionic strength dependence of FMN – heme electron transfer in nitric oxide synthase. Journal of Inorganic Biochemistry, 2018, 184, 146-155.	3.5	5
43	Role of an isoform–specific residue at the calmodulin–heme (NO synthase) interface in the FMN – heme electron transfer. FEBS Letters, 2018, 592, 2425-2431.	2.8	4
44	Introduction of d-Phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 725-730.	2.2	3
45	Linker modification reduced the renal uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 195-198.	2.2	2
46	Tc-99m-labeled RGD-conjugated alpha-melanocyte stimulating hormone hybrid peptides with reduced renal uptake. Amino Acids, 2015, 47, 813-823.	2.7	2
47	Effects of the Arg-Pro and Gly-Gly-Nle Moieties on Melanocortin-1 Receptor Binding Affinities of α-MSH Peptides. ACS Medicinal Chemistry Letters, 2013, 4, 1000-1004.	2.8	1
48	Facile preparation of a novel Ga-67-labeled NODAGA-conjugated lactam-cyclized alpha-MSH peptide at room temperature for melanoma targeting. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127627.	2.2	1
49	The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of ^{67}Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 47-55.	1.0	1
50	Novel Al^{18}F-NOTA-Conjugated Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake. Bioconjugate Chemistry, 2022, 33, 982-990.	3.6	1